GlassScriptPhysician profile
Robert G Louis
NPI 1033312608
$931,515.25
in general payments reported to CMS, 2019-2025
20 companies · $248K in 2025
The $248K reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $109K · 2021: $267K · 2022: $112K · 2023: $49K · 2024: $122K · 2025: $248K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $275K · Royalty Or License: $111K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $6,521 · Travel and Lodging: $5,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $275,262.50 |
| Royalty Or License | $111,250.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,400.00 |
| Food and Beverage | $6,520.64 |
| Travel and Lodging | $5,198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Theater. INC. | $792,548.65 | 2019-2025 | |
| Medtronic, INC. | $105,551.21 | 2021-2025 | Stealthstation S8 Platform, Stealth Autoguide System, Mazor X System |
| Penumbra, INC. | $20,800.00 | 2022 | |
| Medtronic USA, INC. | $8,392.83 | 2019-2020 | |
| Karl Storz Endoscopy-America | $3,000.00 | 2020-2021 | |
| Abbott Laboratories | $280.64 | 2019-2024 | Eterna, Penta, Infinity |
| Integra Lifesciences Corporation | $197.74 | 2019-2025 | Cusa Clarity, Codman Hakim, Codman Certas |
| Monteris Medical Corporation | $185.00 | 2025 | Neuroblate |
| Abbvie INC. | $147.51 | 2023-2025 | |
| Nx Development Corp. | $114.70 | 2019 | |
| Longeviti Neuro Solutions INC | $67.65 | 2025 | Clearfit |
| Cerapedics INC. | $50.64 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $43.34 | 2023 | Kinevo 900 |
| Centinel Spine, LLC | $25.52 | 2019 | |
| Insightec,INC | $25.50 | 2024 | Exablate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Analogic Corporation | $25.43 | 2019 | |
| Stryker Corporation | $24.87 | 2020 | |
| Boston Scientific Corporation | $19.20 | 2019 | |
| Lemaitre Vascular, INC. | $14.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,549.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.